Based on the GlycoMimetics Inc stock forecast from 0 analysts, the average analyst target price for GlycoMimetics Inc is not available over the next 12 months. GlycoMimetics Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of GlycoMimetics Inc is Bearish, which is based on 1 positive signals and 6 negative signals. At the last closing, GlycoMimetics Inc’s stock price was USD 0.40. GlycoMimetics Inc’s stock price has changed by -4.93% over the past week, +168.78% over the past month and -70.19% over the last year.
No recent analyst target price found for GlycoMimetics Inc
No recent average analyst rating found for GlycoMimetics Inc
Company Overview GlycoMimetics Inc
GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein. In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland. Read Less
GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid...Read More
Frequently Asked Questions About GlycoMimetics Inc (GLYC) Stock
Stock Target Advisor's fundamental analysis for GlycoMimetics Inc's stock is Bearish.
Unfortunately we do not have enough data on GLYC's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on GLYC's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on GLYC's stock to indicate if its overvalued.
The last closing price of GLYC's stock was USD 0.40.
The most recent market capitalization for GLYC is USD 0.03B.
Unfortunately we do not have enough analyst data on GLYC's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains GlycoMimetics Inc's stock.
As per our most recent records GlycoMimetics Inc has 35 Employees.
GlycoMimetics Inc's registered address is 9708 Medical Center Drive, Rockville, MD, United States, 20850.
You can get more information about it from GlycoMimetics Inc's website at https://www.glycomimetics.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Frequently Asked Questions About GlycoMimetics Inc (GLYC) Stock
Stock Target Advisor's fundamental analysis for GlycoMimetics Inc's stock is Bearish.
Unfortunately we do not have enough data on GLYC's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on GLYC's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on GLYC's stock to indicate if its overvalued.
The last closing price of GLYC's stock was USD 0.40.
The most recent market capitalization for GLYC is USD 0.03B.
Unfortunately we do not have enough analyst data on GLYC's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains GlycoMimetics Inc's stock.
As per our most recent records GlycoMimetics Inc has 35 Employees.
GlycoMimetics Inc's registered address is 9708 Medical Center Drive, Rockville, MD, United States, 20850.
You can get more information about it from GlycoMimetics Inc's website at https://www.glycomimetics.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for GLYC !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
